$CANFJun 17, 2026, 11:00 AMAI processed
Can‐Fite to Pitch Phase‐III Assets (Namodenoson, Piclidenoson) at BIO 2026
AI Summary
Can‐Fite will conduct partnering meetings at the BIO International Convention (June 22–25) to seek licensing and commercialization deals for its late‐stage pipeline, focusing on oncology, liver disease and inflammatory disorders. The company highlights two pivotal Phase III programs — Namodenoson (Phase III for HCC, Phase IIb for MASH, Phase IIa in pancreatic cancer) and Piclidenoson (pivotal Phase III in psoriasis) — a safety database of >1,600 patients, and ~ $20M in upfront/milestone payments from prior regional licensing deals.
Positives
- Company is actively holding partnering meetings at BIO to pursue licensing/commercialization
- Two pivotal Phase III programs (Namodenoson for HCC; Piclidenoson for psoriasis) provide near‑term value drivers
- Existing regional licensing deals have generated roughly $20M in upfront and milestone payments
Negatives
- Pivotal trials are ongoing — no regulatory approvals yet and outcomes are pending
- Monetization to date is modest (~$20M), indicating limited realized cash from partnerships
- Company notes need for additional capital and other standard development risks in forward‑looking statements